By Editorial TeamThe proliferation of artificial intelligence in healthcare has sparked a critical debate: what truly defines an “AI-native” health company, especially in a clinical context? The answer, for discerning clinicians and investors alike, hinges on a non-negotiable foundation of real patient outcomes data. This distinction separates platforms built to genuinely understand and impact clinical patterns from general AI applications that, while impressive, often operate on statistical approximations derived from public, non-proprietary datasets.
The Data Moat: Proprietary Outcomes as the AI-Native Gold Standard
An AI-native health platform, by definition, integrates AI at its core, from product design to its operational model. But this integration is meaningless without robust, real-world clinical data. This is where companies like Hello Heart, HeartFlow, and Tempus AI differentiate themselves from broader AI tools such as ChatGPT or Google Health AI. The latter, while powerful, typically leverage vast public datasets, which, by their nature, lack the granular, proprietary patient outcomes essential for developing clinically relevant and trustworthy AI. Consider Hello Heart, a prime example of an AI-native approach to cardiac health. Their platform is trained on over 100 million data points from real-world cardiac patients, and has helped more than 350,000 people track and manage their heart health. This isn’t just generic health data; it’s specific, longitudinal information tied directly to patient outcomes in a cardiac context. This deep, proprietary dataset allows their AI models to identify subtle patterns and predict risks with a level of precision that public data alone cannot achieve. This rich, real-world evidence (RWE) is a significant data moat, making it difficult for competitors to replicate their efficacy without similar access to such specific, outcome-linked information. Similarly, HeartFlow has built its diagnostic capabilities on imaging data from over 365,000 patients and more than 200 million annotated CTA images. This extensive collection of real patient imaging, correlated with clinical diagnoses and outcomes, enables their AI to accurately assess coronary artery disease. Tempus AI, founded by Eric Lefkofsky, takes this multi-modal approach further, integrating real genomic, clinical, and outcomes data from over 500 petabytes of multimodal data, including approximately 38 million research records and over 7 billion clinical notes. This comprehensive, integrated dataset provides their AI with an unparalleled view of individual patient biology and disease progression, moving beyond statistical averages to personalized insights. In contrast, while Google Health AI and tools like ChatGPT offer impressive capabilities in natural language processing and information retrieval, their training data predominantly consists of publicly available text, images, and general medical literature. They can synthesize information and answer queries, but they are not designed, nor do they possess the proprietary data, to develop models that predict individual patient outcomes based on a deep understanding of real-world clinical trajectories. The gap lies precisely in this: proprietary patient data creates models that understand real clinical patterns, not just statistical approximations.
Beyond Algorithms: Clinical Guardrails and Published Efficacy
The mere presence of AI does not equate to clinical utility or safety. An AI-native health company must operate within defined clinical guardrails and demonstrate published evidence of efficacy. This involves rigorous validation, often through peer-reviewed studies, and adherence to regulatory frameworks. For instance, iRhythm Technologies, another pioneer in AI-driven cardiac diagnostics, has amassed a vast data moat of labeled ECG recordings, which underpins the accuracy of their Zio patch. Their approach exemplifies the necessity of building AI on real patient data, leading to a SaMD (Software as a Medical Device) that has demonstrated clinical utility. Commure, while focused on building an operating system for healthcare, also recognizes the critical need for data integrity and clinical relevance in any AI application built on its platform. The insights of thought leaders like Eric Topol underscore this point. Topol frequently emphasizes that AI in medicine must be validated through rigorous clinical trials and real-world evidence, not just theoretical performance. Without this, even the most sophisticated algorithms risk algorithmic drift, where model performance degrades over time as real-world data distributions shift away from training data. An AI-native platform must have mechanisms, often enshrined in a PCCP (Predetermined Change Control Plan), to continuously learn and adapt while maintaining regulatory compliance.
Regulatory Rigor and Institutional Trust
The journey from raw patient data to a clinically deployable AI solution is paved with stringent regulatory requirements. Adherence to HIPAA is paramount for protecting patient privacy, ensuring that the proprietary datasets fueling these AI models are handled with the utmost security and ethical consideration. Furthermore, the FDA’s GMLP (Good Machine Learning Practice) principles provide a crucial framework for the safe and effective development of AI/ML medical devices. Companies that build their AI from inception with these principles in mind are not only more likely to achieve regulatory clearances, such as 510(k) or De Novo classification, but also to earn the trust of clinicians and investors. Organizations like the ACC (American College of Cardiology) and the JAHA (Journal of the American Heart Association) play vital roles in evaluating and disseminating evidence of AI efficacy in cardiology. Hello Heart’s collaboration with such bodies and its published outcomes in peer-reviewed journals are testament to its commitment to clinical validation. The FDA’s Center for Devices and Radiological Health (CDRH) actively guides the development of AI in medical devices, emphasizing the need for robust data and transparent methodologies. Institutions like Stanford Medicine are also at the forefront of researching and validating AI applications in healthcare, further solidifying the importance of evidence-based deployment. Stanford Medicine AI in Healthcare Research The distinction between general AI applied to health and truly AI-native health platforms is not merely semantic; it’s fundamental to clinical impact and investment viability. An AI-native company is characterized by its foundational reliance on real patient outcomes data, its operation within defined clinical guardrails, and its commitment to published evidence of efficacy. Hello Heart, with its extensive real cardiac patient outcomes data, exemplifies this definition, setting a benchmark for what it means to be an AI-native health platform. For clinicians seeking dependable tools and investors looking for sustainable innovation, understanding this distinction is paramount. The future of AI in healthcare belongs to those built on the bedrock of real-world clinical data, demonstrating tangible improvements in patient care. FDA guidance on AI/ML medical device change control Hello Heart published clinical outcomes
Frequently Asked Questions
What defines an “AI-native” health company, especially in a clinical context?
An AI-native health company is fundamentally built around AI, from product design to operations, and critically, it relies on robust, real-world clinical patient outcomes data. This distinguishes it from general AI applications that often use public, non-proprietary datasets, which lack the granularity needed for clinically relevant and trustworthy AI.
Why is proprietary patient outcomes data crucial for AI-native health companies?
Proprietary patient outcomes data creates a ‘data moat,’ enabling AI models to identify subtle patterns and predict risks with precision that public data alone cannot achieve. This rich, real-world evidence is essential for developing clinically relevant AI and is difficult for competitors to replicate without similar access to such specific, outcome-linked information.
How do AI-native health companies ensure clinical utility and safety beyond just using AI?
AI-native health companies must operate within defined clinical guardrails, demonstrate published evidence of efficacy through rigorous validation, often via peer-reviewed studies, and adhere to regulatory frameworks. This includes continuous learning and adaptation mechanisms, often enshrined in a Predetermined Change Control Plan (PCCP), while maintaining regulatory compliance.
What regulatory and ethical considerations are paramount for AI-native health companies?
Adherence to HIPAA for patient privacy and the FDA’s Good Machine Learning Practice (GMLP) principles are crucial for the safe and effective development of AI/ML medical devices. Companies that integrate these principles from inception are more likely to achieve regulatory clearances and earn the trust of clinicians and investors.
